Pro-Dex, Inc.

Pro-Dex, Inc.

PDEXNYSE / NASDAQHealthcareSmall cap

$63.00-$0.49 (-0.8%)

Last close · Data as of Nov 20, 2026

Market cap
$213.9M
P/E
23.8x
EV / EBITDA
16.3x
Revenue
$66.6M
Net margin
13.5%
ROCE
23.0%

+104.3% over the last year

Pro-Dex, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+6.1%
3M
-5.0%
6M
-0.7%
1Y
+104.3%
5Y
+208.2%

52-week range

Day change -$0.49 (-0.8%) from $63 to $63 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in PDEX, bought on each weekday since 2021.

News & filings

What Pro-Dex filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernOperating cash flow was -1.7 million US dollars in fiscal 2025, a year of net profit.

Strengths (1)

  • Return on capital employed of 23.0%.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. It offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

Read moreShow less

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. It offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. Its products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

Sector
Healthcare
Shares outstanding
3.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$213.9M
P/E
23.8x
P/B
5.8x
EV / EBITDA
16.3x
EV / Sales
3.5x
P/S
3.2x
52-week high
$73.41
52-week low
$30.83

Profitability

Operating margin
16.1%
Net margin
13.5%
EBITDA margin
21.2%
ROE
24.5%
ROCE
23.0%
ROIC
18.2%
ROA
14.7%
Asset turnover
1.09

Growth

Revenue
$66.6M
Revenue growth, 1Y
23.7%
Revenue CAGR, 3Y
16.6%
Net profit growth, 1Y
322.1%
Free cash flow
-$2.9M

Solvency

Current ratio
3.23
Debt / Equity
0.45
Debt / Assets
0.27
CFO / Net profit
-0.19
Cash / Market cap
0.2%

Where the revenue went

Of every $100 of FY2025 revenue, $13 was left as net income.

Pro-Dex, Inc. income statement flow, FY2025
Pro-Dex, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$47.1M
RevenueGross profit$19.5M
Gross profitResearch and development$3.6M
Gross profitSelling, general and administrative$5.2M
Gross profitOther operating expenses$0.00
Gross profitOperating income$10.7M
Operating incomePretax income$10.7M
Interest and other incomePretax income$1.4M
Pretax incomeTax and other$3.1M
Pretax incomeNet income$9.0M

Revenue and net profit

Revenue grew 23.7% in FY2025; net profit is the dashed line.

Pro-Dex, Inc. revenue and net profit by fiscal year
Pro-Dex, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$42.0M$4.6M
FY2023$46.1M$7.1M
FY2024$53.8M$2.1M
FY2025$66.6M$9.0M

Cash flows

FY2025: -$1.7M from operations, -$2.9M free after investment (dashed).

Pro-Dex, Inc. operating and free cash flow by fiscal year
Pro-Dex, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$847.0k-$2.5M
FY2023$5.5M$4.5M
FY2024$6.2M$5.2M
FY2025-$1.7M-$2.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$66.6M+23.7%1Y
EBITDA
$14.1M+224.6%1Y
Net profit
$9.0M+322.1%1Y
Cash from operations
-$1.7M-127.0%1Y
Free cash flow
-$2.9M-155.9%1Y
Revenue CAGR, 3Y
16.6%
Net profit CAGR, 3Y
25.2%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$66.6M$14.1M$9.0M-$2.9M24.5%+23.7%+322.1%

Monthly returns

Month-by-month returns of PDEX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$61.2M
Liabilities$24.6M
Equity$36.6M
Retained earnings$35.9M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; PDEX highlighted.

P/E against peers

PDEX trades at 23.8x earnings against a peer median of -2.7x.

  1. Pro-Dex, Inc. (this company)23.8x

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Fulcrum Therapeutics, Inc., Inhibikase Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Pro-Dex, Inc.PDEXthis company$213.9M23.8x5.8x24.5%16.3x
Fulcrum Therapeutics, Inc.FULC$224.6M—0.6x-21.5%—
Foghorn Therapeutics Inc.FHTX$219.6M-3.0x-2.0x68.5%-2.3x
Inhibikase Therapeutics, Inc.IKT$219.2M-4.5x1.3x-27.9%-1.5x
Voyager Therapeutics, Inc.VYGR$218.7M-1.8x1.1x-61.1%-1.5x
Utah Medical Products, Inc.UTMD$216.5M19.2x1.8x9.5%9.1x
Keros Therapeutics, Inc.KROS$213.2M2.4x0.7x28.7%-0.8x
RxSight, Inc.RXST$211.1M-5.4x0.8x-14.1%-5.7x
Atrium Therapeutics, Inc.RNA$210.4M-2.7x1.0x-37.0%0.7x
Peer median—-2.7x0.9x-17.8%-1.5x

Year-to-date ROI

PDEX since 1 January, against earlier years.

Historical volatility

PDEX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Pro-Dex, Inc. operating margin by fiscal year
Pro-Dex, Inc. operating margin by fiscal year
DateOperating margin
FY202212.3%
FY202312.5%
FY202413.3%
FY202516.1%
LineFY2025
Cost of revenueCost Of Revenue$47.1M
Gross profitGross Profit$19.5M
Operating expensesOperating Expense$8.8M
Research and developmentResearch And Development$3.6M
Total expensesTotal Expenses$55.9M
Pretax incomePretax Income$12.1M

Learn while you research

Academy chapters picked for Pro-Dex, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing24% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →